Advertisement

Topics

Latest "FOB Synthesis, Inc." News Stories

20:55 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "FOB Synthesis, Inc." found in our extensive news archives from over 250 global news sources.

More Information about FOB Synthesis, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about FOB Synthesis, Inc. for you to read. Along with our medical data and news we also list FOB Synthesis, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of FOB Synthesis, Inc. Companies for you to search.

Showing "Synthesis" News Articles 1–25 of 647

Saturday 15th December 2018

Twist Bioscience Corp Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27082018] Prices from USD $250

SummaryTwist Bioscience Corp Twist Bioscience is a DNA specializing and development company that develops DNA products ad DNA synthesis process. The company provides products includes DNA pools for gRNA cloning such as unamplified oligo pools, cloningready oligo pools; protein scanning single variant libraries, clonal perfect genes and nonclonal fragments, among others. The company operates in the...


Friday 14th December 2018

Co-Diagnostics, Inc Expands Licensing Opportunities Internationally with Receipt of UK Patent for RapidProbe™ Technology

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been awarded a patent from the United Kingdom Intellectual Property Office related to the Company’s RapidProbe™ probe design technology. Mr. Dwight Egan, CEO of Co-...

Thursday 13th December 2018

Genetic drivers of cerebral blood flow dysfunction in TBI: a speculative synthesis


Wednesday 12th December 2018

An exciting tool for asymmetric synthesis

CDMO Identifies Trends Affecting the Generic Drugs Sector in 2019

NewsA shift to outsourcing, practical innovation, increased reliance on raw material, and faster FDA approvals dominate the sector in 2019.

Almirall and X-Chem Announce Dermatology-Focused Drug Discovery Collaboration

X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications. Under the ...

Tuesday 11th December 2018

Light-induced modification of a carboxylic acid with an aminocyclopropenone

(Kanazawa University) Researchers at Kanazawa University report in The Journal of Organic Chemistry that carboxylic acids, functional groups contained in biomolecules, drugs, and materials can be readily modified by light-induced organic reactions using an aminocyclopropenone. This discovery opens up new pathways for carboxylic acid modification with potential applications including determination ...

PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2019

A Shift to Outsourcing, Practical Innovation, Increased Reliance on Raw Material and Faster FDA Approvals Dominate the Sector in 2019 PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical

Jitsubo Co Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryJitsubo Co Ltd Jitsubo, a subsidiary of Sosei Group Corp, is a biotechnology company that develops, manufactures and commercializes peptide therapeutics. The company's molecular hiving technology modifies the polysaccharide and sugar chain peptide sequence. Its Molecular Hiving technology has two part technologies such as thermomorphic system and hydrophobic tag. Jitsubo provide peptide syn...

Monday 10th December 2018

Streamlining the chemoenzymatic synthesis of complex N-glycans by a stop and go strategy

HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest. According to the agreement, HitGen will apply its advanced technology platform, based ...

BryoLogyx Acquires Rights from Stanford University for Bryostatin and Analogues, for Development as Possible Treatment for Cancer And HIV

License Encompasses Related Synthesis of Rare Marine-based Molecule; and Broad Potential Therapeutic Utility BryoLogyx, a privately held company focused on improving on survival rates for patients with cancer announced today it has acquired exclusive rights from Stanford University for synthetic bryostatin-1 and a wide range of bryostatin analogues. Cl...

Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin™ on Muscle Health in Adults in the United States

Clinical Study will be Completed and its Results Announced in the First Half of 2019 Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men...

Sunday 9th December 2018

Libbs Farmaceutica Ltda Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryLibbs Farmaceutica Ltda Libbs Farmaceutica is a pharmaceutical company which manufactures and supply medications for human healthcare. The company offers monoclonal antibodies in various specialties which include cardiovascular, gynecology, oncology, dermatology, respiratory, and central nervous system transplant. It also produces active pharmaceutical ingredients, drugs and other medical p...

USV Pvt Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryUSV Pvt Ltd USV is a healthcare company that offers pharmaceutical products. The company's products include active pharmaceutical ingredients, biosimilars, injectables, ophthalmics, peptides and solid orals. Its biosimilars products comprise PEGfilgrastim, teriparatide, somatropin, filgrastim, plateletderived growth factorBB, epidermal growth factor and glucagon. USV's injectables include s...

Friday 7th December 2018

Making multisectoral collaboration work

A new collection of articles published by The BMJ includes twelve country case studies, each an evaluation of multisectoral collaboration in action at scale on women’s, children’s, and adolescent’s health. Collectively these twelve studies inform an overarching synthesis and accompanying commentaries, drawing together lessons learned in...

Global Undecylenic Acid Market 2018-2022 | Use of Undecylenic Acids as Feedstocks for the Synthesis of Polyurethanes and Polyols to Boost Growth | Technavio

LONDON–(BUSINESS WIRE)–#Research–The global undecylenic acid market is expected to post a CAGR of nearly 5% during the period 2018-2022, according to the latest market research report by Technavio. A key factor driving the growth of the market is the growth … Continue reading →

GENcast: Cancer Diagnostics and PD-L1

Microwave technology for peptide synthesis relies on company’s Liberty series of products. Methodology was designed to reduce reaction rates and waste production. The post GENcast: Cancer Diagnostics and PD-L1 appeared first on GEN - Genetic Engineering and Biotechnology News.

Thursday 6th December 2018

Neuland Laboratories Ltd NEULANDLAB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryNeuland Laboratories Ltd Neuland Lab, a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company provides APIs in various therapeutic segments such as antibacterial, antialzheimer's, antihypertensive, antifungal, bronchodilator, antips...

Wednesday 5th December 2018

AdipoGen Life Sciences immunosuppressive antibiotics

AdipoGen Life Sciences is a provider of key standard antibiotics, rare metabolites/antibiotics and common immunosuppressive antibiotics for use in research. The company’s common immunosuppressive antibiotics are involved in cell proliferation pathways and include calcineurin (FK-506, cyclosporin A, ascomycin), mTOR (everolimus, rapamycin) and purine synthesis (mycophenolic acid) inhibitors. Inh...

Twist Bioscience to Report Fiscal 2018 Fourth Quarter and Full Year Financial Results on Wednesday, December 19, 2018

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2018 following the close of market on Wednesday, December 19, 2018. The company plans to hold a conferenc...

Tuesday 4th December 2018

Type 2 diabetes: A therapeutic avenue is emerging

(INSERM (Institut national de la santé et de la recherche médicale)) Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are developing a therapeutic strategy that uses the properties of an enzyme (hormone-sensitive lipase) which,...

The Dr. Oligo 192c High Throughput Oligo Synthesizer by Biolytic Lab Performance, Inc.

Biolytic introduces the Dr. Oligo 192c - their latest, most advanced synthesizer at a lower price FREMONT, Calif. (PRWEB) December 04, 2018 Biolytic Lab Performance Inc. is proud to announce their latest high throughput oligo synthesizer, the Dr. Oligo 192c, built on Biolytic’s Molecule Synthesis Platform. Now restructured with all the same principles and key design aspects that have allowed t...

AGC Enters Agreement to Acquire Synthetic Pharmaceutical Active Ingredient-manufacturing Plant in Spain

- Acquisition Will Give AGC Foothold in Europe and Broaden Its Pharma CDMO Business - TOKYO, Dec. 4, 2018 /PRNewswire/ -- AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech materials, has announced that it has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals S.L.U. ("MPC"). MPC is a subsidiary of Boehringer Ingelheim that man...

Monday 3rd December 2018

Sequence-defined multifunctional polyethers via liquid-phase synthesis with molecular sieving


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks